Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 82.35

-4.5%

Jan 8 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (1958)	2/13/2008 12:04:22 PM
From: Jibacoa	of 3722

ELN is bouncing up from the $25 level in spite of its > 300% larger loss in the 3rdQ, but It forecasted a 30% rise in revenues over the coming year on rising demand for Tysabri. bigcharts.marketwatch.com It said that it remains confident that they will have 100,000 patients on Tysabri by the end of 2010, with the drug achieving sales of $1B in the next 12 months or so, helped by the fact that it will soon be available in the US for treatment of Crohn's. The loss in the 3rdQ was about $0.02 > the "analysts" expectations.<g> Revenues of $218.3M were 31% better than the $166.4M in 2006 The stock needs to close above its Feb4 H of $26.88 in order to make a 3Yr H. The next important resistance is the Feb 2005 of $29.93 which is close to the Nov 2004 H of $30.45 bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next